Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 376

recruiting
3 972
countries
28
conditions
2 123

10 535 trials match your criteria

Safety of autologous NK cells with IL‑15 and CD45RA‑negative T cells with NKG2D CAR in children, adolescents and young adults with high‑grade brain tumors

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:AUTOLOGOUS PERIPHERAL BLOOD-DERIVED CD45RA- T-CELLS TRANSDUCED WITH A LENTIVIRAL VECTOR ENCODING A CHIMERIC ANTIGEN RECEPTOR AGAINST NKG2-D TYPE II INTEGRAL MEMBRANE PROTEIN

Obinutuzumab in patients with pure class V lupus nephritis (systemic lupus erythematosus membranous nephropathy) – phase II trial

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab

Labour induction

Not yet recruiting

Oral sodium hydrogen carbonate versus placebo to reduce assisted delivery in nulliparous women with prolonged labour

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Sodium Hydrogen Carbonate

Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis: Phase 2/3 Open‑Label and Randomized Placebo‑Controlled Study

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pegcetacoplan

Safety and Tolerability of Lutetium‑177 Vipivotide Tetraxetan Combined with Gozetotide in Women with Metastatic Triple‑Negative Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Gozetotide

Phase II Study of Cemiplimab to Spare Surgery in Patients with Locally Advanced Cutaneous Squamous Cell Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab

Ischaemic stroke

Not yet recruiting

Phase 2 Study of RADAMTS13 in Adults with Acute Ischemic Stroke

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:RADAMTS13

Adenomatous polyposis coli

Not yet recruiting

Study of REC-4881 in Adults with Familial Adenomatous Polyposis to Assess Safety and Efficacy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:TAK-733

Plasma cell myeloma

Not yet recruiting

Reduced vs Standard Dose Belantamab Mafodotin with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Phase II MRD‑Guided Study

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin

Bacterial infection

Not yet recruiting

Model‑informed precision dosing of linezolid in ICU patients with bacterial pneumonia, skin or soft‑tissue infection: a randomized clinical trial

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Linezolid

Urinary tract infection

Not yet recruiting

Preventing urinary tract infections in infants and children under 2 years with oral Escherichia coli strain Nissle 1917 probiotic: a randomized controlled trial

Registered drug
Countries:FinlandFinland
  • Participants:0–17 years
  • Substances:Escherichia coli strain Nissle 1917

Transitional cell carcinoma

Not yet recruiting

Phase Ib/II Study of LP-184 in Patients with Advanced or Metastatic Urothelial Carcinoma

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Zirdafulven
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.